Pamela L. Paris, PhD


Adjunct Professor, Department of Urology, UCSF

Phone: (415) 514-2559 (voice)
Box 3110, UCSF
San Francisco, CA 94143-3110

View on UCSF Profiles


John Carroll University, Cleveland, Ohio, B.S., 1992, Chemistry
University of Rochester, Rochester, New York, M.S., 1995, Biophysical Chemistry
University of Rochester, Rochester, New York, Ph.D., 1998, Biophysical Chemistry
Cleveland Clinic Foundation, Cleveland, Ohio, Postdoc, 1998-2001, Prostate cancer genetics
University of California at San Francisco, San Francisco, California, Postdoc, 2001-2003, Prostate cancer genomics

Professional Experience

  • 1993-1998
    Graduate Student, University of Rochester, Rochester, New York (Advisor: Eric T. Kool)
  • 1998-2001
    Postdoctoral Research Fellow, Cleveland Clinic Foundation, Lerner Research Institute, Cancer Biology Department, Cleveland, Ohio
  • 2001-2003
    Translational Research Fellow, Prostate SPORE, Dept of Urology, UCSF, San Francisco, CA
  • 2003-2006
    Assistant Researcher, UCSF Comprehensive Cancer Center, San Francisco, California
  • 2006-2009
    Associate Researcher, Department of Urology, UCSF, San Francisco, California
  • 2009-2012
    Associate Adjunct Professor, Department of Urology, UCSF, San Francisco, California
  • 2010-present
    Joint Appointment, Division of Hematology-Oncology, Department of Medicine, UCSF
  • 2010-present
    UCSF Helen Diller Family Comprehensive Cancer Center Member
  • 2012-present
    Professor, Department of Urology, UCSF

Honors & Awards

  • 1990
    Phi Lambda Upsilon, Honorary Chemical Society
  • 1992
    Magna cum laude
  • 1993-1998
    Sherman Clarke Fellow
  • 1995-1996
    Merck Fellow
  • 2000
    Society for Basic Urologic Research Travel Award
  • 2001-2003
    UCSF Prostate Cancer Research Fellow
  • 2003-present
    NCI Cancer Prevention and Epidemiology Review Committee
  • 2005
    Gordon Research Conference (New Frontiers: Cancer Detection and Diagnosis) Poster Award
  • 2005
    UCSF, Prostate Cancer Annual Retreat, Poster Award
  • 2008
    Longevity Consortium Member

Selected Publications

  1. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris PL, Zhang Z, Petritsch C, Gupta N, Waldman TA, James CD. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014 Nov 17.
    View on PubMed
  2. Wang J, Paris PL, Chen J, Ngo V, Yao H, Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, Bondada S, Kirkwood K, Sen S. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett. 2015 Jan 28; 356(2 Pt B):404-9.
    View on PubMed
  3. Heselmeyer-Haddad KM, Berroa Garcia LY, Bradley A, Hernandez L, Hu Y, Habermann JK, Dumke C, Thorns C, Perner S, Pestova E, Burke C, Chowdhury SA, Schwartz R, Schäffer AA, Paris PL, Ried T. Single-Cell Genetic Analysis Reveals Insights into Clonal Development of Prostate Cancers and Indicates Loss of PTEN as a Marker of Poor Prognosis. Am J Pathol. 2014 Oct; 184(10):2671-86.
    View on PubMed
  4. Levin AM, Lindquist KJ, Avila A, Witte JS, Paris PL, Rybicki BA. Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) Tumor Biomarker for Identifying Recurrent Disease in African American Patients. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1677-82.
    View on PubMed
  5. Nagarajan RP, Zhang B, Bell RJ, Johnson BE, Olshen AB, Sundaram V, Li D, Graham AE, Diaz A, Fouse SD, Smirnov I, Song J, Paris PL, Wang T, Costello JF. Recurrent epimutations activate gene body promoters in primary glioblastoma. Genome Res. 2014 May; 24(5):761-74.
    View on PubMed
  6. Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer. 2014 May 15; 134(10):2284-93.
    View on PubMed
  7. Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2014 Jun; 142(3):271-80.
    View on PubMed
  8. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012 Feb 1; 72(3):616-25.
    View on PubMed
  9. Ritz A, Paris PL, Ittmann MM, Collins C, Raphael BJ. Detection of recurrent rearrangement breakpoints from copy number data. BMC Bioinformatics. 2011; 12:114.
    View on PubMed
  10. Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, Carroll P, Collins C. A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res. 2010 Jan 1; 16(1):195-202.
    View on PubMed
  11. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, Simko J, Chen WT, Rosenberg J. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett. 2009 May 18; 277(2):164-73.
    View on PubMed
  12. Paris PL. A whole-genome amplification protocol for a wide variety of DNAs, including those from formalin-fixed and paraffin-embedded tissue. Methods Mol Biol. 2009; 556:89-98.
    View on PubMed
  13. Paris PL, Sridharan S, Hittelman AB, Kobayashi Y, Perner S, Huang G, Simko J, Carroll P, Rubin MA, Collins C. An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer. Prostate Cancer Prostatic Dis. 2009; 12(2):184-91.
    View on PubMed
  14. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008 Jun 1; 14(11):3380-5.
    View on PubMed
  15. Raphael BJ, Volik S, Yu P, Wu C, Huang G, Linardopoulou EV, Trask BJ, Waldman F, Costello J, Pienta KJ, Mills GB, Bajsarowicz K, Kobayashi Y, Sridharan S, Paris PL, Tao Q, Aerni SJ, Brown RP, Bashir A, Gray JW, Cheng JF, de Jong P, Nefedov M, Ried T, Padilla-Nash HM, Collins CC. A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol. 2008; 9(3):R59.
    View on PubMed
  16. Hittelman A, Sridharan S, Roy R, Fridlyand J, Loda M, Collins C, Paris PL. Evaluation of whole genome amplification protocols for array and oligonucleotide CGH. Diagn Mol Pathol. 2007 Dec; 16(4):198-206.
    View on PubMed
  17. Paris PL, Sridharan S, Scheffer A, Tsalenko A, Bruhn L, Collins C. High resolution oligonucleotide CGH using DNA from archived prostate tissue. Prostate. 2007 Sep 15; 67(13):1447-55.
    View on PubMed
  18. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007 Jun; 31(6):882-8.
    View on PubMed
  19. Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol. 2007 May; 212(1):91-101.
    View on PubMed
  20. Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll PR, Rubin MA, Collins C. Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer. Neoplasia. 2006 Dec; 8(12):1083-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI